-
公开(公告)号:US5607950A
公开(公告)日:1997-03-04
申请号:US195888
申请日:1994-02-10
IPC分类号: C07D207/08 , C07D211/34 , C07D405/06 , A61K31/445 , A61K31/40
CPC分类号: C07D207/08 , C07D211/34 , C07D405/06
摘要: The invetion is a method of treating irritable bowel syndrome with a compound selected from the formula ##STR1## wherein R, R.sup.1, m, n p are as defined in the specification, or a pharmaceutically acceptable salt thereof.
摘要翻译: 这种侵袭是用选自下式的化合物治疗肠易激综合征的方法:其中R,R 1,m,n p如说明书中所定义,或其药学上可接受的盐。
-
公开(公告)号:US5096890A
公开(公告)日:1992-03-17
申请号:US493068
申请日:1990-03-13
IPC分类号: A61K31/40 , A61K31/4025 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61P1/00 , A61P11/00 , A61P25/02 , C07D207/06 , C07D207/08 , C07D207/09 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12
CPC分类号: C07D207/08 , C07D401/06 , C07D405/06
摘要: Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.
摘要翻译: 吡咯烷毒蕈碱受体拮抗剂,特别可用于治疗肠易激综合征,具有下式: -
及其药学上可接受的盐,其中Y是直链,-CH 2 - , - (CH 2)2 - , - CH 2 O- 或-CH 2 S- R是-CN或-CONH 2; 并且R 1是下式的基团:其中X和X 1各自独立地为O或CH 2; m为1,2或3; “Het”是吡啶基,吡嗪基或噻吩基。 你 -
公开(公告)号:US5340831A
公开(公告)日:1994-08-23
申请号:US859471
申请日:1990-06-12
IPC分类号: A61K31/40 , A61P25/02 , C07D207/08 , C07D207/09
CPC分类号: C07D207/08
摘要: Muscarinic receptor antagonists of formula (I), and their pharmaceutically acceptable salts, wherein Y is --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O--, --(CH.sub.2).sub.2 O-- or --CH.sub.2 S--; R is --CH or --CONH.sub.2 ; and R.sup.1 is a group of formula (a), where R.sup.2 and R.sup.3 are each independently H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --(CH.sub.2).sub.n OH, halo, trifluoromethyl, cyano, --(CH.sub.2).sub.n NR.sup.4 R.sup.5, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), --CH(OH)(C.sub.1 -C.sub.4 alkyl), --C(OH)(C.sub.1 -C.sub.4 alkyl.sub.2, --SO.sub.2 NH.sub.2, --(CH.sub.2).sub.n CONR.sup.6 R.sup.7 or --(CH.sub.2).sub.n COO(C.sub.1 -C.sub.4 alkyl); R.sup.4 is H or C.sub.1 -C.sub.4 alkyl; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkysulphonyl; R.sup.6 and R.sup.7 are each independently H or C.sub.1 -C.sub.4 alkyl; and n is 0, 1 or 2. The compounds are particularly useful in treating irritable bowel syndrome.
摘要翻译: PCT No.PCT / EP90 / 02043 Sec。 371日期:1992年6月12日 102(e)日期1992年6月12日PCT 1990年11月29日PCT PCT。 出版物WO91 / 09013 1991年6月21日,式(I)的蕈毒类受体拮抗剂及其药学上可接受的盐,其中Y为-CH 2 - , - (CH 2)2 - , - CH 2 O - , - (CH 2)2 O-或-CH 2 S- ; R是-CH或-CONH 2; 并且R 1是式(a)的基团,其中R 2和R 3各自独立地为H,C 1 -C 4烷基,C 1 -C 4烷氧基, - (CH 2)n OH,卤素,三氟甲基,氰基, - (CH 2)n NR 4 R 5,-CO (C1-C4烷基),-OCO(C1-C4烷基),-CH(OH)(C1-C4烷基),-C(OH)(C1-C4烷基2,-SO2NH2, - (CH2)nCONR6R7或 - CH2)nCOO(C1-C4烷基); R4是H或C1-C4烷基; R5是H,C1-C4烷基或C1-C4烷基磺酰基; R6和R7各自独立地是H或C1-C4烷基;并且n是0 ,1或2.该化合物特别可用于治疗肠易激综合征。
-
公开(公告)号:US5300516A
公开(公告)日:1994-04-05
申请号:US859728
申请日:1992-06-11
IPC分类号: A61K31/445 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/451 , A61P25/02 , C07D211/88 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D405/14
CPC分类号: C07D405/12 , C07D211/88
摘要: Musacarinic receptor antagonists, particularly useful in the treatment of irritable bowel syndrome, of formula (I), or a pharmaceutically acceptable salt thereof, where m is 1 or 2; R.sup.1 and R.sup.2 are each independently H or C.sub.1 -C.sub.4 alkyl or together represent --(CH.sub.2).sub.p -- where p is an integer of from 2 to 5; R.sup.3 is H or C.sub.1 -C.sub.4 alkyl; wherein Z is a direct link; --CH.sub.2 --, --CH.sub.2 O-- or --CH.sub.2 S--; and R.sup.4 is a group of formulae (II), (III), (IV) or Het, where R.sup.5 and R.sup.6 are each independently H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --(CH.sub.2).sub.n OH, halo, trifluoromethyl, cyano, --(CH.sub.2).sub.n NR.sup.7 R.sup.8, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), --CH(OH)(C.sub.1 -C.sub.4 alkyl), --C(OH)(C.sub.1 -C.sub.4 alkyl).sub.2, --SO.sub.2 NH.sub.2 , (CH.sub.2).sub.n CONR.sup.7 R.sup.8 or --(CH.sub.2).sub.n COO(C.sub.1 -C.sub.4 alkyl); R.sup.7 and R.sup.8 are each independently H or C.sub.1 -C.sub.4 alkyl; n is 0, 1 or 2; X and X.sup.1 are each independently O or CH.sub.2 ; q is 1, 2 or 3; and "Het" is pyridyl, pyrazinyl or thienyl.
摘要翻译: PCT No.PCT / EP90 / 02040 Sec。 371日期:1992年6月11日 102(e)日期1992年6月11日PCT 1990年11月28日PCT PCT。 公开号WO91 / 09014 日期:1991年6月27日。式(I)所示的特别可用于治疗肠易激综合征的马卡拉林受体拮抗剂或其药学上可接受的盐,其中m为1或2; R 1和R 2各自独立地为H或C 1 -C 4烷基或一起表示 - (CH 2)p - ,其中p为2至5的整数; R3是H或C1-C4烷基; 其中Z是直接链接; -CH 2 - , - CH 2 O-或-CH 2 S-; 并且R 4是式(II),(III),(IV)或Het的基团,其中R 5和R 6各自独立地为H,C 1 -C 4烷基,C 1 -C 4烷氧基, - (CH 2)n OH,卤素, 氰基, - (CH2)nNR7R8,-CO(C1-C4烷基),-OCO(C1-C4烷基),-CH(OH)(C1-C4烷基),-C(OH) ,-SO 2 NH 2,(CH 2)n CONR 7 R 8或 - (CH 2)n COO(C 1 -C 4烷基); R 7和R 8各自独立地为H或C 1 -C 4烷基; n为0,1或2; X和X 1各自独立地为O或CH 2; q为1,2或3; “Het”是吡啶基,吡嗪基或噻吩基。
-
公开(公告)号:US5281601A
公开(公告)日:1994-01-25
申请号:US859489
申请日:1992-06-12
IPC分类号: A61K31/445 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61P1/12 , C07D401/04 , C07D405/14 , C07D409/14 , C07D401/14
CPC分类号: C07D401/04 , C07D405/14
摘要: A series of novel 3-phenyl-3-[1-(cyclicalkyl)pyrrolidin-3-yl]glutarimide derivatives have been prepared, including their pharmaceutically acceptable salts. The cyclic moiety present in these compounds is derived from either benzene or a heteroaryl such as benzofuran or 2,3-dihydrobenzofuran, or it is derived from an aromatic heterocyclic such as pyridine, pyrazine or thiophene, and it is attached to the adjacent alkyl group of the molecule by means of one of the available ring carbon atoms situated in the aromatic ring of the aforementioned cyclic ring moiety. These particular compounds are useful in therapy as selective muscarinic receptor antagonists, which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites and therefore, are of value in the treatment of diseases associated with altered motility and/or smooth muscle tone as found in the gut, trachea and bladder. Methods for preparing these compounds from known starting materials are provided.
摘要翻译: PCT No.PCT / EP90 / 02042 Sec。 371日期:1992年6月12日 102(e)日期1992年6月12日PCT提交1989年11月28日PCT公布。 公开号WO91 / 09015 日期1991年6月27日。已经制备了一系列新的3-苯基-3-(1-(环烷基)吡咯烷-3-基)戊二酰亚胺衍生物,包括其药学上可接受的盐。 存在于这些化合物中的环状部分衍生自苯或杂芳基如苯并呋喃或2,3-二氢苯并呋喃,或其衍生自芳族杂环如吡啶,吡嗪或噻吩,并且其连接到相邻的烷基 的分子通过位于上述环状部分的芳环中的可用环碳原子之一。 这些特定的化合物可用于作为选择性毒蕈碱受体拮抗剂的治疗,其对于在心脏毒蕈碱位点上的平滑肌毒蕈碱位点是选择性的,因此在治疗与改变的运动性和/或平滑肌张力相关的疾病中有价值 肠,气管和膀胱。 提供了从已知原料制备这些化合物的方法。
-
公开(公告)号:US5233053A
公开(公告)日:1993-08-03
申请号:US800191
申请日:1992-02-07
IPC分类号: C07D207/08 , C07D401/06 , C07D405/06
CPC分类号: C07D207/08 , C07D401/06 , C07D405/06
摘要: Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.
摘要翻译: 式IMA的化合物其中R,Y和R 1如说明书中所定义。 这些化合物是毒蕈碱受体拮抗剂,其对于心脏毒蕈碱位点的平滑肌毒蕈碱位点是选择性的,并且可用于治疗与平滑肌色调变化相关的疾病,包括肠易激综合征,憩室疾病,尿失禁,食管贲门失弛缓症 和慢性阻塞性气道疾病。
-
公开(公告)号:US5422358A
公开(公告)日:1995-06-06
申请号:US678941
申请日:1991-04-29
IPC分类号: A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/451 , A61K31/495 , A61P1/00 , A61P25/02 , C07D211/34 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12
CPC分类号: C07D405/06 , C07D211/34
摘要: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein: Y is a direct link, --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O-- or --CH.sub.2 S--; R is --CN or --CONH.sub.2 ; and R.sup.1 is ##STR2## where X and X.sup.1 are each independently O or CH.sub.2 ; and m is 1, 2 or 3, are muscarinic receptor antagonists useful in the treatment of diseases and conditions associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome.
摘要翻译: PCT No.PCT / EP89 / 01300 Sec。 371日期:1991年4月29日 102(e)日期1991年4月29日PCT提交1989年10月26日PCT公布。 WO90 / 05133 PCT出版物 日期:1990年5月17日。式(I)化合物及其药学上可接受的盐,其中:Y是直链,-CH 2 - , - (CH 2)2 - , - CH 2 O-或-CH 2 S- - R是-CN或-CONH 2; 并且R1是
,其中X和X1各自独立地为O或CH2; 并且m为1,2或3是可用于治疗与改变的平滑肌的运动性和/或音调(例如肠易激综合征)相关的疾病和病症的毒蕈碱受体拮抗剂。 -
公开(公告)号:US5302595A
公开(公告)日:1994-04-12
申请号:US2498
申请日:1993-01-06
IPC分类号: A61K31/00 , A61K31/335 , A61K31/34 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61P25/02 , C07C237/20 , C07C237/24 , C07C255/42 , C07C255/47 , C07C255/58 , C07C311/08 , C07C311/29 , C07C311/39 , C07C323/25 , C07C323/36 , C07C323/38 , C07C323/49 , C07C323/62 , C07C323/67 , C07D213/38 , C07D213/74 , C07D241/12 , C07D307/79 , C07D311/84 , C07D313/12 , C07D317/58 , C07D319/16 , C07D319/18 , C07D335/14 , C07D337/12 , A61K31/495 , C07D241/02 , C07D333/36
CPC分类号: C07D307/79 , C07C237/20 , C07C237/24 , C07C255/42 , C07C255/47 , C07C255/58 , C07C311/08 , C07D213/38 , C07D317/58 , C07D319/16 , C07C2102/08 , C07C2103/38
摘要: Compounds of the formula I ##STR1## wherein X, Y and v are as defined below, novel intermediates used in their synthesis, and the pharmaceutically acceptable salts of such compounds and intermediates. The compounds of formula I and the novel intermediates used in their synthesis are muscarinic receptor antagonists that are selected for smooth muscle muscarinic sites and are useful in the prevention and treatment of diseases associated with altered motility or tone of smooth muscle, such as irritable bowel syndrome, diverticular disease, urinary incontinence, aesophageal achalasia, and chronic obstructive airways disease.
摘要翻译: 其中X,Y和v如下所定义的式I的化合物,其合成中使用的新中间体,以及这些化合物和中间体的药学上可接受的盐。 式Ⅰ化合物及其合成中使用的新型中间体是选择用于平滑肌毒蕈碱位点的毒蕈碱受体拮抗剂,可用于预防和治疗与改变的平滑肌运动或调节相关的疾病,如肠易激综合征 ,憩室疾病,尿失禁,食管贲门失弛缓症和慢性阻塞性气道疾病。
-
公开(公告)号:US5219871A
公开(公告)日:1993-06-15
申请号:US416894
申请日:1989-10-04
IPC分类号: A61K31/00 , A61K31/335 , A61K31/34 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61P25/02 , C07C237/20 , C07C237/24 , C07C255/42 , C07C255/47 , C07C255/58 , C07C311/08 , C07C311/29 , C07C311/39 , C07C323/25 , C07C323/36 , C07C323/38 , C07C323/49 , C07C323/62 , C07C323/67 , C07D213/38 , C07D213/74 , C07D241/12 , C07D307/79 , C07D311/84 , C07D313/12 , C07D317/58 , C07D319/16 , C07D319/18 , C07D335/14 , C07D337/12
CPC分类号: C07D307/79 , C07C237/20 , C07C237/24 , C07C255/42 , C07C255/47 , C07C255/58 , C07C311/08 , C07D213/38 , C07D317/58 , C07D319/16 , C07C2102/08 , C07C2103/38
摘要: Compounds of the formula I ##STR1## wherein X, Y and v are as defined below, novel intermediates used in their synthesis, and the pharmaceutically acceptable salts of such compounds and intermediates. The compounds of formula I and the novel intermediates used in their synthesis are muscarinic receptor antagonists that are selected for smooth muscle muscarinic sites and are useful in the prevention and treatment of diseases associated with altered motility or tone of smooth muscle, such as irritable bowel syndrome, diverticular disease, urinary incontinence, aesophageal achalasia, and chronic obstructive airways disease.
-
公开(公告)号:US5418229A
公开(公告)日:1995-05-23
申请号:US251037
申请日:1994-05-31
申请人: David Alker , Peter E. Cross
发明人: David Alker , Peter E. Cross
IPC分类号: C07D243/38 , C07D401/12 , C07D405/12 , C07D471/04 , A61K31/55
CPC分类号: C07D401/12 , C07D243/38 , C07D405/12 , C07D471/04
摘要: A compound of the formula ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup..sup.4, Y, m and n are defined herein are useful as muscarinic receptor antagonists.
摘要翻译: 其中X,R 1,R 2,R 3,R 4,Y,m和n如本文所定义的式I化合物可用作毒蕈碱受体拮抗剂。
-
-
-
-
-
-
-
-
-